Sign in to view content

Differences in Intravitreal Silicone Oil Following Multiple Bevacizumab, Ranibizumab, and Aflibercept Injections

John T. Thompson, MD

Video
Published 2019

John T. Thompson, MD

AMD Neovascular Part II Symposium

Related

Foveal Capillary Perfusion Density Decreases in Diabetics with DME Treated on a Fixed Regimen of Intravitreal Aflibercept Injections Over 24 Months
Brittney Statler, MD
Updates from the Field
2020
FIDO Study: 10-Year Outcomes of Eyes Receiving Continuous, Fixed-Interval Dosing of Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
Ivan J. Suner, MD, MBA
Annual Meeting Talks
2019
Prophylaxis Intravitreal Aflibercept Against Conversion to Neovascular AMD in High-Risk Eyes (PRO-CON): 24-Month Results
Jeffrey S. Heier, MD
Annual Meeting Talks
2019

Category: AMD-Neovascular

See more